newsfilter
← Latest News
GlobeNewswire·

LENZ Therapeutics Reports Third Quarter 2024 Financial Results

New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug Administration (FDA); PDUFA target action date of August 8, 2025 CORXEL and LENZ